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Abstract
Progress toward determining the true worth of ongoing practices or value of recent innovations can be glacially
slow when we insist on following the conventional stepwise scientific pathway. Moreover, a widely accepted but
flawed conceptual paradigm often proves difficult to challenge, modify or reject. Yet, most experienced clinicians,
educators and clinical scientists privately entertain untested ideas about how care could or should be improved,
even if the supporting evidence base is currently thin or non-existent. This symposium encouraged experts to share
such intriguing but unproven concepts, each based upon what the speaker considered a logical but unproven
rationale. Such free interchange invited dialog that pointed toward new or neglected lines of research needed to
improve care of the critically ill. In this summary of those presentations, a brief background outlines the rationale for
each novel and deliberately provocative unconfirmed idea endorsed by the presenter.
Keywords: Innovation, Paradigm, Ascorbic acid, Lactate, Nanotechnology, Post-intensive care syndrome, Nutritional
support, Antibiotic overuse, Subcellular microscopy, Lithium
Introduction
The pathway to verified science often begins with intu-
ition or flashes of insight. Without question, we need
rigorous testing and confirmation before widespread
implementation of a proposed innovation for medical
practice. What seems to make conceptual sense is often
proven wrong. In our field of critical care, however, it
can be argued that what has become the traditional
method of truth seeking has let us down. Attractive as it
might seem, the clinical trial crucible is imperfect, ineffi-
cient, and applicable to a highly restricted number of
testable questions. The list is long regarding initially ac-
cepted practices derived from the clinical trials base that
later were overturned by more recent and more nuanced
studies. Negative clinical trials tell us relatively little.
Progress in our field, though undoubtedly real, has been
rather slow and inefficient, prompting some experts to
rethink the entire process of testing and validation. Yet,
most experienced clinicians, educators, and clinical sci-
entists privately entertain untested ideas about how care
could or should be improved, even if the supporting evi-
dence base is currently thin or non-existent. The follow-
ing symposium encouraged each presenter to describe a
personal favorite but unproven idea that might serve as
a conceptual starting point along new or neglected lines
of research or treatment aimed at improving care of the
critically ill. We caution that although each presentation
drew from well-established observations, the interpreta-
tions, extensions, and implications made by the pre-
senters remain their own: speculative and unverified—at
least for now.
Unproven ideas for future critical care practice
Daniel De Backer: use of vitamin C as a therapeutic adjunct
in sepsis
Background: While being around for some time for its
anti-oxidant properties, vitamin C has been recently
pushed under spotlight by a publication of Marik et al.
suggesting that vitamin C, in addition to hydrocortisone
and thiamine, may improve organ function and survival
[1]. While this study has many limitations including its
before/after design, this publication generated a lot of
enthusiasm and several trials are nowadays underway
trying to replicate these findings.
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Vitamin C seems to have pleiotropic effects in sep-
sis. Vitamin C has been shown to increase arterial
pressure in septic patients [1, 2], and this effect may
be mediated by an increase in tetrahydrobiopterin
availability, promoting catecholamine and vasopressin
synthesis [2].
Vitamin C seems also to have beneficial effects on the
microvasculature. In experimental sepsis, vitamin C im-
proved microvascular perfusion. Interestingly, this pro-
tective microvascular effect remained effective even
when vitamin C was administered up to 24 h after the
onset of sepsis. This effect is dependent on endothelial
NO synthase [3] and may be mediated by its impact on
tetrahydrobiopterin, an essential cofactor of NO syn-
thase. Interestingly, while promoting NO production on
endothelial NO synthase, vitamin C also inhibits indu-
cible NO synthase, limiting the production of detrimen-
tal radical species and in particular peroxynitrite.
However, even though vitamin C improved micro-
vascular perfusion, it has limited impact on other
markers of endothelial function. In particular, it failed to
blunt the increase in endothelial permeability [4].
Hence, it seems that vitamin C may have interesting
effects in sepsis, in particular through an improvement
of endothelial reactivity and in microvascular perfusion.
However, there remain many unsolved questions includ-
ing adequate patient selection (should it be based on dis-
ease severity or based on vitamin c plasma levels?);
timing of intervention (Just after initial resuscitation? At
recognition of disease? As rescue therapy?); best dosing
scheme, administered in isolation or combined with
thiamine and hydrocortisone; and toxicity. These ques-
tions need to be solved in order to transform this
unconfirmed idea into a clinical use.
Idea: Appropriately dosed vitamin C is a low-risk,
low-cost, and potentially helpful addition to our current
armamentarium used against sepsis and septic shock.
Luciano Gattinoni: impaired cellular O2 utilization, not
sufficient perfusion and O2 availability, is the underlying
defect causing “lactic acidosis” in most cases of septic
shock
Background: Aggressive fluid resuscitation has become
an accepted cornerstone of sepsis management, driven
by the belief that hypotension and hyperlactatemia
usually arise from inadequate oxygen availability in vital
tissues [5]. However, hyperlactatemia may occur inde-
pendently of tissue oxygen availability, as indicated by
the coexistence of hyperlactatemia and low, normal, or
high central venous oxygen saturation (ScvO2). In the
absence of hypoxemia, central venous oxygen desatur-
ation, although an imperfect marker, generally indicates
greater than normal O2 extraction elicited by presumed
inadequacy of O2 delivery. Yet, ScvO2 often remains
normal in sepsis, even as metabolic acidosis proceeds.
Moreover although the coexistence of hyperlactatemia
and low pH is conventionally referred to as “lactic acid-
osis,” the direct link between excess lactate and acidemia
is not straightforward [6]. In the traditional view, lactate
and free protons [lactic acid] are the “abnormal” prod-
ucts of glycolysis in anoxic tissue. Yet, according to the
“lactate shuttle theory,” lactate is the “normal” (i.e.,
expected) end-product of glycolysis, regardless of the
oxygen tissue tension, is normally produced without a
net release of free protons, and does not directly affect
pH [7]. Thus, although lactate is a useful marker of the
severity of shock [8], well-functioning kidneys regulate
the electrolyte balance, compensating for the challenge
to ionic balance, and acidemia seldom develops. In the
absence of fully compensatory mechanisms, however,
any excess of lactate must result in a negative base ex-
cess. In septic patients, such compensations may or may
not be present, and therefore, there is no direct associ-
ation between lactate levels and acidemia. Indeed, arter-
ial pH, lactate, and ScvO2—which according to the
traditional interpretative view should be tightly inter-
linked—are often present in contradictory combinations.
Maintenance of normal ScvO2 suggests that targeting a
further boost in oxygen delivery to peripheral tissues,
e.g., by vigorous fluid administration, may be a misdir-
ected response to lactic acidosis—especially when kidney
perfusion and function are well preserved.
Idea: Modulation of the aggressiveness of fluid resusci-
tation in accordance with measurements of ScvO2 and
determination of the base excess component not attrib-
utable to lactate—the “alactic base excess,” a simple
calculation that could help assess renal compensating
ability for the stress of metabolic acidosis.
Can Ince: functional imaging of living cells in vivo
Background: In recent years, remote imaging of the
tubular structures of the gastrointestinal tract has been
accomplished by radiofrequency communication from
small ingested camera capsules. Although less invasive
than traditional endoscopy, such methods simply establish
the feasibility of acquiring anatomical data non-invasively
at sites far removed from the caregiver. In the not so dis-
tant future, this principle will be extended to the cellular
level within vasculature of key vital organs [9]. Perhaps
more importantly, such imaging and tissue targeting may
afford the opportunity to anatomically focus our interven-
tions, such as drug delivery and assess their effects. Tech-
niques already in development demonstrate the ability of
synthetic biology devices to locate and tag vital tissues of
interest [10]. Three currently being investigated are
Caspase (apoptotic) tracking, specially engineered bacteria
that home to tumor cells and tag by bioluminescence, and
Marini et al. Critical Care 2019, 23(Suppl 1):197 Page 2 of 7
cell-type classifiers that determine key gene expressions
and release marker molecules (Fig. 1).
Delivery of such trackers and of drugs may be actively
driven by “micromotors” which are very small (micro-
n-sized) particles that can move themselves [11]. These
micromotors propel themselves in a specific direction
autonomously when placed in a chemically appropriate
liquid environment. Although potentially there are
several different micromotor types and mechanisms
applicable to medicine, key examples naturally occurring
are the biological motors of bacteria and other self-pro-
pelled cells. Synthetically, researchers have exploited
oxidation-reduction reactions to produce chemical
gradients, local fluid flows, or streams of bubbles that
propel these synthetic micromotors through the chem-
ical media of body fluids. Methodologies to image their
transit and that of other markers must be considered in
the early stage of development.
Dynamic, contrast-enhanced ultrasound (CEUS) has
been used experimentally to determine bubble transit
time and thereby characterize perfusion through the
microcirculation of the normal and sepsis altered kid-
ney [12]. Other imaging methodologies that show
considerable promise for bedside use include side-
stream and incident darkfield imaging hand-held vital
microscopes [13]. Such hand-held vital microscopes
have been shown capable of imaging the richness and
filling of microvessels and in identifying and quantify-
ing leukocytes in the microcirculation of accessible
tissues (e.g., sublingual) in a variety of non-invasive
and surgical settings [14]. Although progress has been
rapid, to this point, tissues substantially deeper than
the subsurface layer remain out of reach by these
methodologies. The time does not seem so far off
that precision medicine will be abetted by intravascu-
lar telemetric nano-imaging, self-propelled searching
capsules, in vivo functional assessment of targeted cell
function, and the imaging of the benefit and conse-
quences of drug delivery.
Idea: Microcirculatory imaging, cellular function
assessment, and tissue-specific therapeutic targeting by
nano-biotechnology.
John J. Marini: cognitive decline during and following ICU
care may be averted by encouraging cues that maintain
normal variations of physiology and behavior
Background: As often said, “variety is the spice of life.”
More than that, variations of physiology, alertness, and
cognition are essential components and markers of
health; loss of such variations characterizes depleted
reserves and serious, life-threatening illness [15]. For
example, variations of respiratory breathing depth and
rhythm exemplify effortless breathing, whereas the
stress of exercise narrows that variation to a more
Fig. 1 Plausible future tools for in vivo imaging, “theradiagnostics,” and precision drug delivery
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metronome-like pattern. Narrowing of heart rhythm
variability has been linked to loss of cardiac reserve.
Circadian rhythms of many organ systems, e.g., certain
key stress hormones, e.g., cortisol, also blunted by crit-
ical illness and are not restored by such uni-modal ICU
interventions as light variation [16]. In the throes of the
initial crisis, the body responds to the challenge by
exuberant and often dysfunctional responses. As clini-
cians, we seek to blunt those responses and to
“stabilize” physiologic parameters. Understandably, our
initial goal is to achieve a viable plateau and to
minimize variations from our set standard. We provide
monotonous tidal volumes, fluid infusions, vasopres-
sors, and feedings. We suppress alertness, conscious-
ness, and pain. These interventions, while appropriate
for the initial stage, have the well-recognized potential
for harm when inappropriately prolonged [15].
The post-intensive care syndrome (PICS) is a pervasive
and highly morbid consequence of critical illness and its
management. Current approaches to its prevention focus
on early mobilization, attention to avoiding excessive
sedation, preventing delirium [17], and preserving sleep
quality. These help preserve muscle strength and in the
prevention and treatment of delirium [18]. Recent trials of
non-pharmacologic interventions, however, have yielded
disappointing results [19]. No approach to date has been
shown to halt PICS-associated cognitive decline.
Another common adage is that “what you do not use,
you lose.” Myriad physical and psychosocial signals nor-
mally keep the healthy brain oriented to the variability
of daily life, and functional reinforcement and pruning
of synaptic pathways may be occurring continually, espe-
cially during sleep [20]. Extraction of the patient from
the familiar to the unfamiliar, threatening, and monoton-
ous routines of the ICU that that normal environment
may be adversely train the brain, forming dysfunctional
connections and pruning away many that are normally
used. It is also possible that monotonous two-way cross-
talk between body and brain may deliver neuronal mes-
sages of ongoing disease, rather than of recovering
health and resilience. Finally, as sustained isolation of
even the healthy mind suggests, delirium might be the
“default state” to which we might all regress if removed
from re-orienting cues of daily living.
Idea: We should prioritize maintenance of normal
daily psychosocial interactions and variations of activity
during the post-resuscitation and recovery phases of
ICU care to help prevent cognitive decline and debility.
Ignacio Martin-Loeches: highly personalized medicine to
optimize sepsis management and outcomes
Background: At present, sepsis remains a potentially
lethal condition approached from the platform of
imprecise working diagnosis. Some patients benefit from
this style of management, whereas many others receive
little benefit or are even harmed by our attempts to help.
Although somewhat controversial, a significant body of
evidence indicates that early administration of appropri-
ate antibiotics aids in achieving a satisfactory result.
Currently, the two components of this strategy, appro-
priate antibiotics and early intervention, are both sub-
optimal. Lacking accurate microbiological diagnosis at
treatment onset, powerful broad spectrum antibiotics
with unwanted side effects are typically given that are
later pared and/or replaced once the organism and
sensitivities are known. In a significant number of cases,
the responsible organism responsible for sepsis—if any—
remains unknown. Likewise, we have made clear pro-
gress toward earlier antimicrobial intervention, but sys-
temic logistical delays between order and “hang time”
occur all too commonly along the “supply chain” of crit-
ical care delivery. Currently deployed biomarkers such
as procalcitonin and c-reactive protein help establish
and quantitate the intensity of tissue injury response but
do not nail the responsible organism.
The response of the host to the septic challenge is a
key and largely under-supported determinant of out-
come. Some patients have an overly exuberant defensive
response to the infective challenge that extends the at-
tack to healthy tissues (e.g., vasoplegia and ARDS),
whereas others are constitutively or functionally im-
munosuppressed and need a boost. For example, hydro-
cortisone may benefit those with plasma cytokine levels
above a certain threshold, whereas others are not helped
(or even injured) by steroid therapy [21]. On the other
hand, polyclonal antibodies to boost immunity may
benefit only those whose concentrations of immuno-
globulins and inflammatory markers are low and high,
respectively. Even when such evaluations can be imple-
mented, not all septic patients will benefit; the degree of
organ dysfunction, as indicated by the SOFA score, may
be a helpful determinant of responsiveness.
A variety of well-established and newer tools for im-
proving diagnostic and therapeutic precision are on the
near horizon [22]. Nanotechnologies hold promise to
quickly diagnose, selectively treat, and monitor the root
causes of these septic conditions [23]. Apart from im-
proved precision of antibiotic targeting, other novel
treatments have shown exciting potential. For example,
in well-selected patients, exogenous mesenchymal stem
cells (MSCs) may help treat sepsis by their intrinsic abil-
ity to home to injured tissue, secrete paracrine signals to
limit systemic and local inflammation, decrease apop-
tosis in threatened tissues, stimulate neoangiogenesis,
activate resident stem cells, beneficially modulate im-
mune cells, and exhibit direct antimicrobial activity.
These effects are associated with reduced organ
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dysfunction and improved survival in animal models. Fi-
nally, agents such as cilengitide may prevent adherence
of pathogens such as Staphylococcus aureus and Escheri-
chia coli to the blood vessel endothelium, with experi-
mentally demonstrated therapeutic benefit [24].
Idea: Utilize newer precision tools to rapidly identify
the underlying causes, select well-targeted treatments,
and boost host responses to sepsis.
Mervyn Singer: restricted and abbreviated use of
antimicrobials for infection
Background: Few therapies are as well entrenched in
ICU practice as the early and aggressive use of antibi-
otics to suppress infection [25]. A well-discussed and
appropriate concern is the need to avoid the indiscrim-
inate use of these agents to prevent emergence of
life-threatening microbial resistance to these vital
armaments. Yet, the idea that appropriate antibiotics are
invariably helpful when infection develops is never ser-
iously challenged. It may be wise to re-examine this
mandate. Antibiotics are effective not only against the
offending organism but also the host tissues, as well.
Apart from their widely acknowledged potential for side
effects, renal and hepatic dysfunction, the ability of
certain agents to impair mitochondrial function (e.g.,
linezolid) [26] and to adversely alter both immunity and
the microbiome is extensively documented. Few would
withhold an effective antimicrobial in the face of a
known symptomatic infection. However, considering
their predictable tendencies to produce adverse conse-
quences, one might logically wonder: “Just how solid is
the evidence that antibiotics reduce mortality?” It turns
out, less reassuring than one might think.
Many patients survived what might be considered
life-threatening illnesses in the pre-antibiotic era. Early
comparisons of sulphonamide antibiotics with placebo
demonstrated a modest reduction of mortality from
pneumonia, but an increased incidence of complications
(e.g., empyema). In the pre-antibiotic eras that preceded
our own, surgery of chest and abdomen for advanced in-
fections was frequently successful without their use. In
more recent years, enthusiasm for earliest possible anti-
biotic intervention has waned with the demonstration by
multiple prospective studies that reasonable delays make
very little difference to eventual outcome of sepsis and
septic shock [25, 27]. Some experimental data indicate
that the rapid early release of bacterial cell products by
bactericidal antibiotics exacerbate severity. In certain set-
tings, biomarker-targeted decisions for antibiotic interven-
tion rather than automatic broad spectrum coverage may
often make better sense [28], and de-escalation strategies
for life-threatening infections appear to offer a survival ad-
vantage over sustained antibiotic treatment. Very recent
reports indicate that fewer antibiotics and shorter
treatment courses lessen adverse side effects and might
even improve survival. Indeed, courses as brief as 1–3 days
may be as effective as those traditionally recommended
[29]. Taken together, such data prompt careful consider-
ation of the need for antibiotic treatment and urge that
targeted antibiotics be given for the shortest effective
time.
Idea: Curtail the duration of antimicrobial treatment and
avoid the use of antibiotics whenever feasible to do so.
Pierre Singer: precision nutrition for intensive care
Background: The sustained stresses of critical illness re-
quire appropriate and individualized nutritional support
but often outstrip our current attempts to provide it.
These shortcomings undoubtedly contribute to deficits
that contribute to lasting disability that is both difficult
and slow to repair. Our current approaches are rather
indiscriminate, fail to scale appropriately to individual
needs, and are unmodified during the changing require-
ments during the rescue, recovery, and re-strengthening
phases of the patient’s ICU trajectory. Deficits of calories
and protein develop quickly and early in the hospital
course, deepening as the relatively immotile gut is un-
able to accept full target loads by the enteral route, often
resulting in regurgitation or interruption of enteral
administration. Moreover, the gastrointestinal tract may
not absorb with normal efficiency (due to edema, etc.)
and insufficient energy is delivered to cope with the
metabolic stress. The natural pattern of intermittent oral
meals almost invariably yields to continuous feedings
with monitoring of gastric residuals—is nutritional
support provided at all during the initial demanding
phase? Finally, assessment of nutritional balance—re-
quirements and demands—is currently confined to rela-
tively crude and/or slowly reactive measurements of
serum proteins such as albumin and its precursors, elec-
trolytes, and glucose.
There has been substantial progress along multiple
fronts to address these shortcomings [30]. Among many
advances, the gut microbiome perhaps has received the
most attention for its value in determining and assessing
patient health status. Although of intense interest, this
element of nutritional science does not stand alone.
Smart nasogastric tubes that sense and maintain appro-
priate gut positioning and nutrient infusion rates (so as
to avoid intolerance, regurgitation and vomiting) should
help reach nutritional goals and avoid both discomfort
and complications.
Improved understanding and recent innovations in
technology and informatics that are applicable to the
bedside promise to advance the precision and appropri-
ateness of our future nutritional care. For example, the
quantity of exhaled carbon dioxide can be noninvasively
measure on an ongoing basis to give a clearer picture of
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the energy needs. The burgeoning fields of metabolo-
mics and proteomics hold the potential to assess nutri-
tional status, set appropriate adjustments of the nutrient
mix, and monitor progress through the varied stages of
acute illness. Recent evidence indicates that such
enhanced precision may be profitably integrated into se-
verity of illness indexes such as the SOFA score, cluster
analyses, and inflammatory cytokine marker profiles to
prognosticate with enhanced proficiency the outcome of
life-threatening sepsis [31]. “Big Data” analytics of rele-
vant populations and perhaps of the myriad points of
physiologic data and laboratory variables that pertain to
the individual have only begun to show their decision
support potential [32].
Idea: Utilize modern advances in technological,
molecular science, and informatics to better monitor
and deliver nutritional requirements for optimized and
nuanced care for the individual through all stages of
critical illness.
Martin Westphal: lithium to treat disorders of the “bipolar”
kidney
Background: Lithium is a very reactive metal represent-
ing a key constituent of powerful modern batteries in-
cluding electric cars. Its clinical use goes back to 1847,
when Dr. Alfred Garrod investigated the role of lithium
in the treatment of gout. Interestingly, this approach was
successful only in patients suffering from bipolar disor-
ders as co-morbidity. However, it took more than 100
years to launch lithium as mood stabilizer in patients
with bipolar disorders and to leverage its effects for the
treatment of mania and prophylaxis of manic-depressive
illness (http://www.lowdoselithium.com/the-history).
Recent research in rodent models revealed that lithium
also exerts meaningful neuroprotection in stroke, fragile
X syndrome, amyotrophic lateral sclerosis, and Hunting-
ton’s, Alzheimer’s, and Parkinson’s disease [33]. Among
others, inhibition of glycogen synthase kinase type 3
[GSK3] appears to play a key role in this context. GSK3
is a ubiquitously expressed serine/threonine protein kin-
ase, implicated in the processes of tissue injury, repair,
and regeneration in multiple organ systems. Likewise,
there is evidence that inhibition of this protein kinase
conveys renal protection [34].
In fact, lithium inhibits GSK3, thereby blunting in-
flammation and oxidative stress as well as mediating
kidney tissue repair [35]. It has been shown in a mur-
ine model of lipopolysaccharide [LPS]-elicited acute
kidney injury (AKI) that a single-intraperitoneal injec-
tion of a low dose of lithium chloride [40 mg/kg] at
the time of LPS administration reduces renal tissue
injury, inflammation, and dysfunction, which is associ-
ated with a survival benefit [36]. Likewise, it has been
reported that a delayed administration of lithium
attenuates cisplatin- and ischemia/reperfusion-induced
AKI in a dose-dependent manner. Specifically, lithium
promotes renal tubular epithelia repopulation, im-
proves kidney repair, and accelerates renal salvage.
The authors concluded that pharmacologic targeting
of GSK3 represents a promising approach to treat
established AKI [37].
Currently, lithium is registered neither for prevention
nor for treatment of AKI, but clinical studies are under-
way to elucidate its efficacy. Since high doses of lithium
have been linked to kidney damage in the past [33], a
better understanding of the dose-response relationship is
crucial from a safety point of view. Once the safety is
established, re-purposing lithium with the goal to pre-
vent and treat AKI is straightforward and could make
the depressed kidney happy.
Idea: Low-dose lithium may represent a viable option
both to prevent AKI in patients at risk and to treat
established AKI.
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